Allergy-Focused Circassia Raises £60m, Led by Imperial Innovations
This article was originally published in The Pink Sheet Daily
Executive Summary
Funding round is Europe's fifth-largest in over a decade, underscoring investor confidence in Circassia's T-cell vaccine technology.